Patents by Inventor Iddo Magen

Iddo Magen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DIAGNOSIS OF FRONTOTEMPORAL DEMENTIA
    Publication number: 20220364175
    Abstract: A method of diagnosing Frontotemporal dementia (FTD) in a subject in need thereof is provided. The method comprising detecting a level of at least one micro RNA (miR) selected from the group consisting of hsa-miR-361-5p, hsa-miR-629-5p, hsa-miR-628-3p, hsa-miR-379-5p, hsa-miR-1-3p, hsa-miR-26a-5p, hsa-miR-125a-5p, hsa-miR-125b-5p, hsa-miR-142-5p and hsa-miR-340-5p in a biological sample of the subject, wherein when said level of said at least one micro RNA (miR) is higher than that in a control sample, it is indicative of FTD.
    Type: Application
    Filed: June 22, 2022
    Publication date: November 17, 2022
    Applicants: Yeda Research and Development Co. Ltd., UCL Business Ltd
    Inventors: Eran HORNSTEIN, Iddo MAGEN, Nancy-Sarah YACOVZADA, Jonathan ROHRER, Pietro FRATTA
  • CELL-FREE MIRNA BIOMARKERS FOR PROGNOSIS AND DIAGNOSIS OF NEURODEGENERATIVE DISEASES
    Publication number: 20220220559
    Abstract: A method of prognosing a course of disease progression and/or survival time in a subject diagnosed with ALS or FTD is disclosed. The method comprising: (a) detecting a level of miR-181 in a biological sample of the subject; and (b) determining the disease progression and/or survival time based on the level of the miR-181, wherein: (i) when the level of miR-181 is higher than that in a control sample, it is indicative of a rapid disease progression and/or poor survival; or (ii) when the level of miR-181 is about the same or lower than that in the control sample, it is indicative of a slow disease progression and/or good survival. Methods of prognosing a stage of disease in a subject diagnosed with ALS or FTD are also disclosed.
    Type: Application
    Filed: May 13, 2020
    Publication date: July 14, 2022
    Applicants: Yeda Research And Development Co. Ltd., Queen Mary University London, UCL Business Ltd
    Inventors: Eran HORNSTEIN, Iddo MAGEN, Andrea MALASPINA, Pietro FRATTA
  • Treatment of hepatic encephalopathy and liver cirrhosis
    Patent number: 10166202
    Abstract: The compounds D9-tetrahydrocannabinol (THC), cannabidiol (CBD) and capsaicin are useful for prevention, treatment, or both, of hepatic encephalopathy. The compounds capsaicin, 2-arachidonoylglycerol (2-AG), HU-308 and cannabidiol are useful for prevention, treatment, or both, of liver cirrhosis.
    Type: Grant
    Filed: June 16, 2011
    Date of Patent: January 1, 2019
    Assignees: Yissum Research Development Company of the Hebrew University of Jerusalem, Hadasit Medical Research Services & Development Ltd., Aristotle University of Thessaloniki
    Inventors: Elliot Berry, Yosefa Avraham, Raphael Mechoulam, Yaron Ilan, Yossi Dagon, Iddo Magen, Nicholas Grigoriadis, Theofilos Poutachidis
  • TREATMENT OF HEPATIC ENCEPHALOPATHY AND LIVER CIRRHOSIS
    Publication number: 20110251290
    Abstract: The compounds D9-tetrahydrocannabinol (THC), cannabidiol (CBD) and capsaicin are useful for prevention, treatment, or both, of hepatic encephalopathy. The compounds capsaicin, 2-arachidonoylglycerol (2-AG), HU-308 and cannabidiol are useful for prevention, treatment, or both, of liver cirrhosis.
    Type: Application
    Filed: June 16, 2011
    Publication date: October 13, 2011
    Applicants: Yissum Research Development Company of the Hebrew University of Jerusalem, Aristotle University of Thessaloniki, Hadasit Medical Research Services & Development Ltd.
    Inventors: Elliot BERRY, Yosefa Avraham, Raphael Mechoulam, Yaron Ilan, Yossi Dagon, Iddo Magen, Nicholas Grigoriadis, Theofilos Poutachidis
  • Treatment of hepatic encephalopathy and liver cirrhosis
    Publication number: 20100022631
    Abstract: The compounds D9-tetrahydrocannabinol (THC), cannabidiol (CBD) and capsaicin are useful for prevention, treatment, or both, of hepatic encephalopathy. The compounds capsaicin, 2-arachidonoylglycerol (2-AG), HU-308 and cannabidiol are useful for prevention, treatment, or both, of liver cirrhosis.
    Type: Application
    Filed: April 24, 2009
    Publication date: January 28, 2010
    Applicants: Yissum Research Development Company of the Hebrew University of Jerusalem, Hadasit Medical Research Services & Development Ltd., Aristotle University of Thessaloniki
    Inventors: Elliot BERRY, Yosefa Avraham, Raphael Mechoulam, Yaron Ilan, Yossi Dagon, Iddo Magen, Nicholas Grigoriadis, Theofilos Poutachidis